Steris said on Monday that it has signed a definitive agreement to buy Xodus Medical, a privately held maker of surgical safety products based near Pittsburgh, for $2.1 billion at closing, according to the company's release. It expects the deal to close by 31 December 2026, subject to regulatory approvals, and to finance it primarily with debt. Nothing has closed.
The price is the headline. The profit underneath it is the more interesting number. Steris expects Xodus to generate about $245 million of revenue in calendar 2026 and about $135 million of adjusted EBIT, a margin of about 55 per cent.
What Steris disclosed
Steris said the net purchase price is about $1.8 billion once it counts cash tax benefits with a net present value of about $300 million. The release does not say where those benefits come from. The price is also subject to customary adjustments, and there is up to $150 million more in potential earnout if Xodus meets post-closing performance targets in calendar 2028. The targets were not disclosed.
The release gives the margin only in adjusted form. Steris builds Xodus's adjusted EBIT from projected 2026 operating income of $121 million, plus about $14 million of charges substantially consisting of a royalty arrangement that was terminated during 2026. On the unadjusted figure, the operating margin is about 49 per cent. Steris's own operating margin on a reported basis was about 19 per cent in the June quarter, by our arithmetic from its results. The release does not say who received the royalty or what it cost to end it. Whether the $14 million stays gone is the question on which the adjusted number depends.
By this publication's arithmetic, $2.1 billion is about 8.6 times projected 2026 revenue and about 15.6 times adjusted EBIT. On the $1.8 billion net price, the multiples fall to 7.3 times and 13.3 times. Steris expects the deal to be accretive to top-line growth, margins and adjusted earnings, but gave no earnings figure.
Not quite a pivot
The obvious angle, a sterilization equipment maker moving toward recurring revenue, needs a correction. Steris is already there. In its fiscal 2027 first-quarter results, for the quarter ended 30 June, the company reported consumables revenue of $474.0 million out of $1,492.7 million in total, up from $435.0 million a year earlier. Consumables plus service, which Steris labels recurring, came to $1,229.6 million.
On our arithmetic, consumables were about 32 per cent of revenue and recurring lines about 82 per cent. Capital equipment, at $263.2 million, was about 18 per cent.
So the deal is better read as a bet on one category: single-use products that sit in the operating room and are reordered. Xodus is best known for its Pink Pad system, which secures and stabilizes patients on the operating table to reduce the risk of slipping or pressure injuries, Reuters reported. Its other products include electrosurgical accessories, medication labels, anti-fog products for surgical lenses and safety devices for handling needles and other sharps.
For scale, Steris's Healthcare segment booked $391.9 million of consumables revenue in the June quarter. Multiplying by four gives about $1.57 billion a year, a crude annualization. Xodus's $245 million would be roughly 16 per cent of that. That is our inference from a single quarter, not a Steris forecast. McKesson's deal for half of Option Care last week was another healthcare buyer paying for repeat business.
The buyer, the seller and the analyst
Steris Chief Executive Dan Carestio said in the release that the business "has demonstrated an ability to grow at double-digit rates" with its specialty product portfolio. The release gives no growth figure, and Xodus is private, so there is no filing to check it against. Craig Kaforey, Xodus Medical's chief executive, said joining Steris "marks an exciting new chapter for our company."
Steven Etoch, an analyst at Stephens, called it "a logical tuck-in that adds additional operating-room supplies to Steris' healthcare business," in comments carried by Reuters. He said Steris may be able to lift Xodus's sales through its larger sales network and its relationships with hospital operating rooms. That is the commercial case in one sentence. It is also an untested one.
Goldman Sachs is Steris's exclusive financial adviser and Jones Day its legal counsel. J.P. Morgan advised Xodus, with Morgan, Lewis & Bockius as legal counsel.
Debt and what comes next
Steris reported short-term indebtedness of $243.4 million and long-term indebtedness of $1,650.2 million at 30 June, against cash of $482.3 million. That is about $1.89 billion of gross debt. If the whole $2.1 billion were borrowed, gross debt would roughly double, to about $4.0 billion. Steris said "primarily," not entirely, and has not disclosed the lenders, the mix or the terms. This is our arithmetic, not a company figure.
The deal follows another consumables commitment. In August Steris said it would spend $600 million on a center in Sanford, North Carolina, which the governor's office said would create 335 jobs in Lee County. Reuters described that hub as making and distributing formulated chemicals for healthcare sterilization and pharmaceutical production. It is a different kind of consumable from a surgical pad, but it draws on the same balance sheet.
Two things will settle the question. The first is the outlook. In August Steris reiterated fiscal 2027 adjusted earnings of $11.10 to $11.30 per diluted share, and it says it will give a revised outlook including Xodus only after closing. The second is regulatory review, where the release names no agency or timetable beyond year-end.
The price, net price, tax-benefit value, earnout, Xodus revenue, adjusted EBIT, the $121 million operating income and $14 million adjustment, financing, closing timetable, accretion statement, advisers and the Carestio and Kaforey statements come from Steris's release of 12 October 2026. Steris's quarterly revenue lines, operating income, debt, cash and fiscal 2027 outlook come from its fiscal 2027 first-quarter results of 5 August 2026 filed with the SEC. The Pink Pad description, the product list, the description of the North Carolina hub and Steven Etoch's comments come from Reuters reporting of 12 October 2026, as carried by KSL. The $600 million figure, Sanford location and 335 jobs are from the North Carolina governor's office, 5 August 2026. The multiples, margins, consumables and recurring shares, the annualized Healthcare consumables comparison and the pro forma debt figure are this publication's arithmetic. The analysis is our own.
Topics businesshealthcareacquisitions
